QGEN - QIAGEN N.V.

NYSE - Nasdaq Real Time Price. Currency in USD
37.07
-0.43 (-1.15%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close0.00
Open37.30
Bid0.00 x 1300
Ask0.00 x 1400
Day's Range0.00 - 0.00
52 Week Range
Volume749,003
Avg. Volume1,246,504
Market Cap8.414B
Beta (3Y Monthly)0.87
PE Ratio (TTM)45.77
EPS (TTM)0.81
Earnings DateJul 29, 2019 - Aug 2, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est40.89
Trade prices are not sourced from all markets
  • QIAGEN Partners Inovio to Develop Companion Diagnostics
    Zacks3 days ago

    QIAGEN Partners Inovio to Develop Companion Diagnostics

    QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.

  • Benzinga3 days ago

    The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...

  • PR Newswire3 days ago

    Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

    Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to respond to VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus virus (HPV). This precision medicine partnership focuses on Inovio's VGX-3100, a late-stage product candidate currently in two pivotal Phase 3 clinical trials (REVEAL 1 and 2) with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.

  • Business Wire3 days ago

    QIAGEN and Inovio Collaborate to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions

    Frankfurt Prime Standard:QIA) and Inovio Pharmaceuticals Inc. (INO) today announced a collaboration to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus (HPV). The Precision Medicine partnership focuses on Inovio’s VGX-3100, a late-stage investigational product candidate with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.

  • Markit6 days ago

    See what the IHS Markit Score report has to say about Qiagen NV.

    Qiagen NV NYSE:QGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for QGEN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting QGEN. Money flowETF/Index ownership | PositiveETF activity is positive but appears to be weakening. Over the last month, growth of ETFs holding QGEN is favorable, with net inflows of $4.11 billion. This is among the highest periods of net inflows seen over the last one-year, but the rate of additional flows appears to be decreasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Qiagen Looks to Growth in the Second Half of the Year
    Motley Fool6 days ago

    Qiagen Looks to Growth in the Second Half of the Year

    The QIAstat should accelerate growth for the diagnostic testing company.

  • Thomson Reuters StreetEvents7 days ago

    Edited Transcript of QGEN earnings conference call or presentation 7-May-19 1:00pm GMT

    Q1 2019 Qiagen NV Earnings Call

  • With A 7.2% Return On Equity, Is QIAGEN N.V. (NYSE:QGEN) A Quality Stock?
    Simply Wall St.10 days ago

    With A 7.2% Return On Equity, Is QIAGEN N.V. (NYSE:QGEN) A Quality Stock?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Business Wire10 days ago

    QIAGEN: Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052/ Share Repurchase

    QIAGEN N.V. announces that it will initiate the repurchase of a fourth tranche of shares under the share repurchase program which was announced by an ad hoc announcement dated January 31, 2018. In the time period between May 10, 2019 until June 18, 2019, at the latest, a fourth tranche of up to 2 million common shares of the Company having a total purchase price of up to USD 50 million (or the equivalent Euro amount thereof, in each case without ancillary purchasing costs) shall be repurchased exclusively on the electronic trading platform of the Frankfurt Stock Exchange (XETRA). The maximum purchase price per share (excluding ancillary purchase costs) will not exceed the average closing price for the last five trading days prior to the day of purchase on the electronic trading platform of the Frankfurt Stock Exchange by more than 10%.

  • GuruFocus.com11 days ago

    Bank of Italy Buys Qiagen NV

    Rome, L6, based Investment company Bank of Italy buys Qiagen NV during the 3-months ended 2019Q1, according to the most recent filings of the investment company, Bank of Italy.

  • Qiagen NV (QGEN) Q1 2019 Earnings Call Transcript
    Motley Fool12 days ago

    Qiagen NV (QGEN) Q1 2019 Earnings Call Transcript

    QGEN earnings call for the period ending March 31, 2019.

  • QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss
    Zacks13 days ago

    QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss

    QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.

  • Qiagen (QGEN) Tops Q1 Earnings Estimates
    Zacks13 days ago

    Qiagen (QGEN) Tops Q1 Earnings Estimates

    Qiagen (QGEN) delivered earnings and revenue surprises of 3.85% and -0.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press13 days ago

    Qiagen: 1Q Earnings Snapshot

    The Venlo, Netherlands-based company said it had profit of 13 cents per share. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, were 27 cents per share. The results ...

  • Business Wire13 days ago

    QIAGEN Reports Results for First Quarter of 2019 and Announces Plans for New $100 Million Share Repurchase Program

    QIAGEN reports results for first quarter of 2019 and announces plans for new $100 million share repurchase program

  • Why Earnings Season Could Be Great for QIAGEN (QGEN)
    Zacks17 days ago

    Why Earnings Season Could Be Great for QIAGEN (QGEN)

    QIAGEN (QGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • Business Wire17 days ago

    QIAGEN Posts 2018 Annual Report on Its Website

    QIAGEN N.V. announced today that it had posted its 2018 Annual Report on its website at http://financialreport.qiagen.com.

  • Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
    Zacks21 days ago

    Qiagen (QGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

    Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire25 days ago

    Biocartis Group NV: BIOCARTIS Q1 2019 BUSINESS UPDATE

    PRESS RELEASE : REGULATED INFORMATION Thursday 25 April 2019, 07:00 CEST BIOCARTIS Q1 2019 BUSINESS UPDATE Mechelen, Belgium , 25 April 2019 - Biocartis Group NV (the `Company` or `Biocartis`), an innovative ...

  • Should QIAGEN (NYSE:QGEN) Be Disappointed With Their 74% Profit?
    Simply Wall St.28 days ago

    Should QIAGEN (NYSE:QGEN) Be Disappointed With Their 74% Profit?

    Stock pickers are generally looking for stocks that will outperform the broader market. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. For example, the QI...

  • Here is What Hedge Funds Think About Qiagen NV (QGEN)
    Insider Monkeylast month

    Here is What Hedge Funds Think About Qiagen NV (QGEN)

    Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]

  • QIAGEN Drives Molecular Diagnostics Suite With New Test Kit
    Zackslast month

    QIAGEN Drives Molecular Diagnostics Suite With New Test Kit

    QIAGEN (QGEN) introduces the FDA approved companion diagnostic test to help in guiding therapy in any cancer identification.

  • Business Wirelast month

    QIAGEN N.V. to Report First Quarter 2019 Results

    QIAGEN N.V. plans as previously announced to release its report on results for the first quarter 2019 on Monday, May 6 at approximately 22:05 Central European Time / 16:05 Eastern Standard Time .